Navigation Links
Arcturus Therapeutics, Inc. Announces an RNAi Therapeutic Targeting Transthyretin-mediated Amyloidosis as its Flagship Program
Date:1/13/2014

SAN DIEGO, Jan. 13, 2014 /PRNewswire/ -- Arcturus Therapeutics, Inc., an industry leader in RNA technologies, today announced its flagship program – an RNAi therapeutic targeting transthyretin (TTR)-mediated amyloidosis.  Preclinical non-human primate data will be presented at the Biotech Showcase being held January 13, 2014 in San Francisco, California.

(Logo: http://photos.prnewswire.com/prnh/20130531/MM24393LOGO)

Preclinical results from a non-human primate (NHP) study demonstrated > 75% knockdown of serum TTR protein levels after 10 days, with the effect sustained over 3 weeks (0.3 mg/kg, i.v. dosing).

In addition to NHP knockdown data, no adverse events were observed using Arcturus LUNARTM delivery technology, in particular, no injection site reactions occurred. Furthermore, a substantial safety window was demonstrated in a multiple dose rat toxicology study – no adverse events observed at the highest doses (30 mg/kg total; administered three times at 10 mg/kg over 15 days). Serum levels of the alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were determined after intravenous administration and no changes in these liver enzymes were observed.

"We are pleased to announce our flagship program targeting TTR including our successful achievement of non-human primate data with durable biological effect and having an impressive safety profile," said Pad Chivukula, Ph.D., Arcturus' CSO and COO. "With this data in hand, we are laser-focused on selecting a wholly-owned clinical drug candidate in 2014 and entering the clinic soon after."

About Transthyretin (TTR)-Mediated Amyloidosis

Transthyretin (TTR)-mediated amyloidosis is a genetically mediated fatal disease caused by mutations in the TTR gene. Mutated TTR, wh
'/>"/>

SOURCE Arcturus Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina Biotech
2. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
3. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
5. Cell Therapeutics, Inc. (CTI) Appoints Former Managing Director, Head of West Coast Biotechnology for Oppenheimer/CIBC Matthew J. Plunkett Executive Vice President, Corporate Development
6. Cell Therapeutics, Inc. (CTI) Reduces Net Loss for Third Quarter and Nine Months Ended September 30, 2012 Compared to Same Periods in 2011
7. Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
8. Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
9. Northwest Biotherapeutics, Inc. Announces Full Exercise of Over- Allotment Option
10. Epigenetics Technology Market (Epigenomics, DNA Methylation, Histone Modifications, RNA Interference, Cancer Therapeutics, Personalized Medicine) (2012 - 2017)
11. Arno Therapeutics, Inc. Appoints Randy Thurman to the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015 ... the concerned market with analysis and forecast of revenue. ... and is estimated to reach $1,177.8 million by 2019, ... Browse through the TOC of Mannequin-Based Simulation ... and segments, with help of various tables and figures. ...
(Date:5/28/2015)... Colo. , May 28, 2015  Array BioPharma ... encorafenib, binimetinib and selumetinib (licensed to AstraZeneca) at the ... which will be held May 29 – June 2, ... three products are currently advancing in a total of ... from both the NEMO (binimetinib monotherapy in NRAS mutant ...
(Date:5/28/2015)... ALBANY, N.Y. , May 28, 2015 /PRNewswire/ ... "503B Outsourcing Facility" under section 503B of the ... for this title, the company is subject to ... oversight, producing bulk medications according to the highest ... 21 CFR Part 211. To continuously comply with ...
Breaking Medicine Technology:Mannequin-Based Simulation Market Report is Expected to Reach $1,177.8 Million by 2019, at a CAGR of 19.4% from 2014 to 2019 2Mannequin-Based Simulation Market Report is Expected to Reach $1,177.8 Million by 2019, at a CAGR of 19.4% from 2014 to 2019 3Array BioPharma Announces Clinical Data Presentations At The 2015 ASCO Annual Meeting 2Array BioPharma Announces Clinical Data Presentations At The 2015 ASCO Annual Meeting 3
... announces the release of VB E ... serialization and traceability regulations for pharmaceutical, biologics, medical device and ... 4.0 for Life Sciences adds support for GS1 standards, ... Verify Brand™ has also gone beyond compliance requirements ...
...   Seminars: February 14-15, 2012 ,Exhibition: February ... largest packaging tradeshow, announced the launch of two new ... 14-16, 2012. The seminars focus on sustainability and automation ... impacting all sectors of the packaging industry. ...
Cached Medicine Technology:Verify Brand™ Announces the Release of VB Enterprise 4.0 for Life Sciences 2Verify Brand™ Announces the Release of VB Enterprise 4.0 for Life Sciences 3WestPack Launches New Sustainability and Automation and Cost Control Seminars 2
(Date:5/28/2015)... 28, 2015 More than 300 locations ... raise money to help the Muscular Dystrophy Association save ... and related life-threatening diseases that limit muscle strength and ... program. , From June 1 to June 30, sweetFrog ... the opportunity to help send local children affected by ...
(Date:5/28/2015)... 2015 ZH Healthcare (ZH), a leading ... is releasing BlueEHS, the Electronic Health Solution, on the ... the benefit of all AWS users worldwide. , ... of its kind, Freemium, SaaS, Electronic Health Solution (EHS). ... with an integrated practice management system (PMS), e-Rx, lab ...
(Date:5/28/2015)... May 28, 2015 CompanionDx ... company, announces that it will present their integrated ... testing at the annual American Society of Clinical ... sequencing evaluates the DNA in a patient’s tumor ... analyzed for key changes or somatic mutations. Pharmacogenomics ...
(Date:5/28/2015)... 28, 2015 Sexual Health Innovations, ... advances sexual health and wellbeing in the United ... San Francisco (USF) will be the first institution ... recording and reporting system. , Callisto is ... confidential reporting experience for college sexual assault survivors, ...
(Date:5/28/2015)... 28, 2015 Cancer survivors who participated ... in physical activity, fitness and quality of life, according ... Cancer Center and Jennifer Ligibel, MD, senior physician in ... Farber Cancer Institute. The findings will be presented at ... Annual Meeting in Chicago. , The ...
Breaking Medicine News(10 mins):Health News:sweetFrog and MDA Join Forces to Send Kids with Muscle Disease to Summer Camp 2Health News:sweetFrog and MDA Join Forces to Send Kids with Muscle Disease to Summer Camp 3Health News:BlueEHS, the Electronic Health Solution, now available on Amazon AWS Market place 2Health News:BlueEHS, the Electronic Health Solution, now available on Amazon AWS Market place 3Health News:CompanionDx® Launches Integrated Genomic Solution at ASCO Meeting 2Health News:University of San Francisco Becomes First in the Nation to Adopt College Sexual Assault Reporting System 2Health News:University of San Francisco Becomes First in the Nation to Adopt College Sexual Assault Reporting System 3Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 2Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 3Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 4
... ... vice president of the company,s Hoosier Region, with one of its two Heartland Division President,s ... ... honored John Conlon, vice president of the company,s Hoosier Region, with one of its two ...
... , ... Capabilities and Added Experience Highlight the New Pediatric Speech Therapy Partnership , ... Atlanta, GA (PRWEB) September 22, ... with school systems across the U.S., is pleased to announce that Travis Consulting, LLC ...
... , Report presents findings by ... , , NEW YORK, Sept. 22 ... in 15 years, and at a time of heightened economic insecurity, new ... trending downward in a number of important areas. The State of ...
... , TAMPA, Fla., Sept. 16 ... announced today that the US Food and Drug Administration (FDA) ... gel) 0.15% as a treatment for acute herpetic keratitis (dendritic ... this indication in April 2007. , , ...
... today [Thursday] estimates nearly 45,000 annual deaths are associated with ... a half times higher than an estimate from the Institute ... Insurance and Mortality in U.S. Adults," appears in today,s [Thursday,s] ... . The Harvard-based researchers found that uninsured, working-age Americans ...
... study in the world of treatments for post menopausal, ... continue to take exemestane or tamoxifen do significantly better ... drug (or tamoxifen followed exemestane) but then stop. ... central data office for TEAM (tamoxifen exemestane adjuvant multinational) ...
Cached Medicine News:Health News:Conlon Wins Life Care's Heartland Division President's Award 2Health News:Cobb Pediatric Therapy Services Joins Forces with Travis Consulting, LLC to Offer Expanded Services Across the U.S. 2Health News:New Families and Work Institute Study Reveals Declines in the Health of American Workforce 2Health News:New Families and Work Institute Study Reveals Declines in the Health of American Workforce 3Health News:New Families and Work Institute Study Reveals Declines in the Health of American Workforce 4Health News:New Families and Work Institute Study Reveals Declines in the Health of American Workforce 5Health News:Sirion Therapeutics Announces FDA Approval of Zirgan(TM) (Ganciclovir Ophthalmic Gel) 0.15% for Herpetic Keratitis 2Health News:Sirion Therapeutics Announces FDA Approval of Zirgan(TM) (Ganciclovir Ophthalmic Gel) 0.15% for Herpetic Keratitis 3Health News:Sirion Therapeutics Announces FDA Approval of Zirgan(TM) (Ganciclovir Ophthalmic Gel) 0.15% for Herpetic Keratitis 4Health News:45,000 excess deaths annually linked to lack of health insurance: Harvard study 2Health News:Study of adjuvant endocrine treatment for breast cancer reveals cost of noncompliance 2Health News:Study of adjuvant endocrine treatment for breast cancer reveals cost of noncompliance 3Health News:Study of adjuvant endocrine treatment for breast cancer reveals cost of noncompliance 4
TOX/See is a 1-step, hand-held, point-of-care device for the qualitative detection of drug or drug metabolites in human urine....
Compact, bench-top analyser with minimal water volume requirements and easy waste management....
Compact benchtop clinical chemistry system...
... offers easy operation, maintenance, and training. Whether you ... to the powerful VITROS 5,1 FS, the VITROS ... right the first time. Its that simple. , ... and easy-to-use. The VITROS 350 comes complete with ...
Medicine Products: